Nora Anderson

734 total citations
8 papers, 601 citations indexed

About

Nora Anderson is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Nora Anderson has authored 8 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 4 papers in Hematology and 3 papers in Rheumatology. Recurrent topics in Nora Anderson's work include Chronic Lymphocytic Leukemia Research (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Eosinophilic Disorders and Syndromes (3 papers). Nora Anderson is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Eosinophilic Disorders and Syndromes (3 papers). Nora Anderson collaborates with scholars based in United States, Germany and United Kingdom. Nora Anderson's co-authors include Jürgen Borlak, Sabine Eckhardt, Natalie J. Serkova, Sven Gottschalk, Jost Klawitter, Uwe Christians, Yan Ling Zhang, Frankie A. Wong, A. Hunt and Junia V. Melo and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Nora Anderson

7 papers receiving 585 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nora Anderson United States 5 265 210 141 97 94 8 601
Karen M. Kassel United States 15 268 1.0× 369 1.8× 52 0.4× 56 0.6× 53 0.6× 20 800
Chiaki FUNAKI Japan 14 173 0.7× 79 0.4× 77 0.5× 54 0.6× 77 0.8× 30 849
Kanichi Asai Japan 15 203 0.8× 69 0.3× 91 0.6× 53 0.5× 78 0.8× 39 848
S. Imes United States 4 219 0.8× 156 0.7× 126 0.9× 36 0.4× 166 1.8× 5 927
Kasumi Yamakawa Japan 11 301 1.1× 129 0.6× 59 0.4× 31 0.3× 99 1.1× 11 710
Emilio Siendones Spain 17 364 1.4× 44 0.2× 72 0.5× 172 1.8× 32 0.3× 22 891
Kevin J. Milliner United Kingdom 11 303 1.1× 196 0.9× 263 1.9× 33 0.3× 159 1.7× 13 892
Agostino Faggiotto United States 8 288 1.1× 244 1.2× 190 1.3× 92 0.9× 153 1.6× 12 1.5k
Nancy W. Bethea United States 13 151 0.6× 174 0.8× 44 0.3× 54 0.6× 19 0.2× 14 684
J. Oiknine Israel 11 179 0.7× 96 0.5× 55 0.4× 37 0.4× 131 1.4× 12 737

Countries citing papers authored by Nora Anderson

Since Specialization
Citations

This map shows the geographic impact of Nora Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nora Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nora Anderson more than expected).

Fields of papers citing papers by Nora Anderson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nora Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nora Anderson. The network helps show where Nora Anderson may publish in the future.

Co-authorship network of co-authors of Nora Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Nora Anderson. A scholar is included among the top collaborators of Nora Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nora Anderson. Nora Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Hunt, A., et al.. (2024). Abstract 2978: Extracellular ATP induced senescence in human lung cancer cells. Cancer Research. 84(6_Supplement). 2978–2978. 1 indexed citations
2.
Klawitter, Jost, Yan Ling Zhang, Nora Anderson, Natalie J. Serkova, & Uwe Christians. (2009). Development and validation of a sensitive assay for the quantification of imatinib using LC/LC‐MS/MS in human whole blood and cell culture. Biomedical Chromatography. 23(12). 1251–1258. 20 indexed citations
3.
Klawitter, Jost, et al.. (2009). Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. British Journal of Cancer. 100(6). 923–931. 44 indexed citations
4.
Anderson, Nora & Jürgen Borlak. (2008). Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacological Reviews. 60(3). 311–357. 319 indexed citations
5.
Gottschalk, Sven, et al.. (2004). Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells. Clinical Cancer Research. 10(19). 6661–6668. 207 indexed citations
6.
Melo, Junia V., László G. Boros, Nora Anderson, et al.. (2004). Metabolic Profile of Imatinib Resistance in CML Cells.. Blood. 104(11). 1982–1982. 1 indexed citations
7.
Anderson, Nora, et al.. (2000). The determination of RWJ-38705 (tramadol N-oxide) and its metabolites in preclinical pharmacokinetic studies using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 22(3). 469–480. 9 indexed citations
8.
Wong, Frankie A., et al.. (1998). Determination of a Synthetic Decapeptide in the Plasma of Monkeys and Rats by Narrowbore Highperformance Liquid Chromatography. Journal of Liquid Chromatography & Related Technologies. 21(7). 1051–1062.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026